In particular, preliminary studies show how MEK inhibition results in increased tumor antigen presentation, promotes T-cell infiltration of the tumor and regulates a number of cytokines, enhancing tumor recognition by the immune system. This evidence concerns the gene MAP2K7 and neoplasm.